<DOC>
	<DOCNO>NCT00886535</DOCNO>
	<brief_summary>This study open-label prospective observational trial design test association polymorphisms candidate gene tamoxifen . Pre- post-menopausal woman take tamoxifen standard therapy chemopreventive therapy include study .</brief_summary>
	<brief_title>Effect Pharmacogenomics Differences Phase I II Metabolism Tamoxifen Efficacy Toxicity</brief_title>
	<detailed_description>This study open-label prospective observational trial design test association polymorphisms candidate gene ( focus initially UGT2B7 enzyme ) tamoxifen ( TAM ) toxicity . Pre- &amp; post-menopausal woman ( age â‰¥18 year ) take TAM ( 20 mg/day ) standard therapy chemopreventive therapy include study . Patients enrol complete primary surgery , radiation , adjuvant chemotherapy . Patients exclude undergoing adjuvant endocrine therapy . Other reason exclusion include patient pregnant lactating , currently corticosteroid , phenobarbital , megestrol acetate . The goal recruit total 45 eligible patient 1 year accrual period . The investigator expect treat ~50 new patient per year TAM standard dose 20 mg/day .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients receive tamoxifen adjuvant therapy breast cancer ductal carcinoma situ , chemoprevention Age 18 year May pre postmenopausal Females Patients may point hormonal treatment , must complete planned surgery , radiation chemotherapy Must use reliable form birth control Pregnant Breastfeeding Concurrent use corticosteroid , megestrol , phenobarbital History allergy tamoxifen Unwilling yearly gynecological exam</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>hot flash</keyword>
	<keyword>tamoxifen</keyword>
</DOC>